1. A method for treating restless legs syndrome (RLS) in patient suffering from RLS, and in need of an effective treatment thereof, comprising: the administration of an effective amount of cabergoline or a pharmacologically acceptable salt thereof. 2. A method of claim 1, wherein said dose of cabergoline is about 0.1 to 6 mg per patient per administration, on an as needed basis. 3. A method of claim 2 wherein said dose of cabergoline is administered once a day. 4. A method of claim 2 wherein said dose of cabergoline is administered 4 or 5 times a week in amounts from about 0.25 to 6 mg per administration. 5. A method of claim 2 wherein said dose of cabergoline is administered 2 or 3 times a week in amounts from about 0.25 to 6 mg per administration. 6. A method of claim 5 wherein said dose of cabergoline is administered once a week in amounts from about 0.25 to 6 mg per administration. 7. A method of claim 1, wherein said dose of Cabergoline is about 0.25 to 4 mg/day. 8. A method of claim 1, wherein said dose of Cabergoline is about 0.25 to 2 mg/day. 9. A method for treating restless legs syndrome (RLS) in patient suffering from RLS, who has previously been treated, or is concurrently being treated with one or more of; a dopamine agonist, a benzodiazepine, or a psychotropoic agent, comprising: the administration of an effective amount of cabergoline or a pharmacologically acceptable salt thereof. 10. A method of claim 9, wherein the previous or concurrent treatment is or was with a dopamine agonist and the dose of Cabergoline is about 0.1 to 6 mg/day. 11. A method of claim 9, wherein said dopamine agonist is or was levodopa. 12. A method of claim 11, wherein said dose of Cabergoline is about 0.25 to 4 mg/day. 13 A method of claim 9, wherein said previous or concurrent treatment is or was with a benzodiazepines and said dose of Cabergoline is about 0.25 to 4 mg/day. 14. A method of claim 13, wherein said benzodiazepine is clonazepam (Klonopin). 15. A method of claim 9, wherein said previous or concurrent treatment is or was with said psychotropoic agent, wherein said psychotropoic agent is an opioid and said dose of Cabergoline is about 0.1 to 4 mg/day. 16. A method for treating restless legs syndrome (RLS) in patient suffering from RLS, where the patient has suffered from or is considered susceptible to suffer from agumentation or rebound effects from a previous treatment for RLS wherein the previous treatment consists of being treated with one or more of ; a dopaminergic agent, a dopamine agonist, a benzodiazepine, or a psychotropoic agent, comprising: the administration of an effective amount of cabergoline or a pharmacologically acceptable salt thereof. 17. A method for treating patients who are not sleeping well, comprising the adminstration of an effective amount of cabergoline or its pharmaceutically acceptable salts. 18. A method of claim 17 where said patients have an abnormal sleep pattern as measured by standard sleep tests. 19. A method of claim 16 where said effective amount of cabergoline is between about 0.25 to 5 mg per patient per day. 20. A method of claim 16 where said previous treatment consisted of being treated with a dopamine agonist, wherein said dopamine agonist is levodopa and said effective amount of cabergoline or salt thereof is from 0.25- 4 mg per patient per day. 21. A method for treating restless legs syndrome (RLS) in patient suffering from RLS, where the patient has suffered from tolerance from a previous treatment for RLS wherein the previous treatment consisted of being treated with one or more of; a dopaminergic agent, a dopamine agonist, a benzodiazepine, or a psychotropoic agent, comprising: the administration of an effective amount of cabergoline or a pharmacologically acceptable salt thereof. 22. A method of claim 21 where said previous treatment consisted of being treated with a dopamine agonist, wherein said dopamine agonist is levodopa and said effective amount of cabergoline or salt thereof is from 0.1- 4 mg per patient per day. 23. A method for treating restless legs syndrome (RLS) in patient suffering from RLS, and in need of an effective treatment thereof, comprising: the administration of an effective amount of cabergoline or a pharmacologically acceptable salt thereof in combination with an effective amount of levodopa or its pharmacologically acceptable salts. 24. A once a day method for treating restless legs syndrome (RLS) in patient suffering from RLS, and in need of an effective treatment thereof, comprising: the administration of an effective amount of cabergoline or a pharmacologically acceptable salt thereof to the patient, once a day. 25. A method for treating restless legs syndrome (RLS) in patient suffering from RLS, and in need of an effective treatment thereof, comprising: the administration of an effective amount of cabergoline or a pharmacologically acceptable salt thereof, but without the administration of another dopaminergic agent. 26. A method for treating restless legs syndrome (RLS) in patient suffering from RLS, and in need of an effective treatment thereof, consisting essentially of: the administration of an effective amount of cabergoline or a pharmacologically acceptable salt thereof. 27. Any treatments of claims 1-26 where the cabergoline is administered to the patient once a day. 28. Any treatments of claims 1-26 where the cabergoline is administered to the patient every other day. 29. Any treatments of claims 1-26 where the cabergoline is administered to the patient about 2-3 times per week. 30. The use of cabergoline or its pharmaceutically acceptable salts in the manufacture of a medicament to treat RLS, and for any of the RLS symptoms described herein.
USE OF CABERGOLINE IN THE TREATMENT OF RESTLESS LEGS SYNDROME